As a leader in data-driven
medicine, SOPHiA GENETICS lends its expertise to
support White House Cancer Moonshot
BOSTON and LAUSANNE, Switzerland, June 2, 2023
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native
software company in the healthcare space and a leader in
data-driven medicine, announced today at ASCO that it
has joined as a founding member of CancerX, a new
public-private partnership formed to rapidly accelerate the pace of
cancer innovation in the United
States. As a founding member, SOPHiA GENETICS will help
drive the success of CancerX, collaborating to set priorities and
practices that will harness the power of innovation to further
cancer care and research. SOPHiA GENETICS offers its
SOPHiA DDM™ Platform, powered by artificial intelligence and
machine learning, to help advance the inaugural project, which
looks to improve equity and reduce cost in cancer
treatments.
CancerX was announced by the White House in February 2023 as part of the reignited national
Cancer Moonshot initiative. Co-hosted by the Moffitt Cancer
Center and the Digital Medicine Society (DiMe), alongside
the Office for the National Coordinator for Health Information
Technology (ONC) and Office of the Assistant Secretary for Health
(OASH), CancerX will unite stakeholders and innovators to unleash
the power of innovation and create a future that is free of the
burden of cancer.
"As a leader in data-driven medicine, SOPHiA GENETICS is eager
to join forces with CancerX and its partners that will lend their
expertise towards expediting cancer research and innovation in the
U.S.," said Kevin Puylaert, Vice President, Business Development
& Marketing for SOPHiA GENETICS. "CancerX founding member
Memorial Sloan Kettering Cancer Center (MSK) is among the 750+
institutions within our global data-sharing network. We look
forward to leveraging the collective intelligence that our platform
creates to help progress cancer research as we embark on our work
with CancerX."
In early 2022, President Biden reignited the Cancer
Moonshot, setting new national goals to cut the death rate from
cancer by at least 50 percent over the next 25 years and improve
the experience of people and their families living with and
surviving cancer. In February 2023,
the White House announced CancerX, which strives to unite a diverse
and inclusive community of stakeholders and harness their
collective superpowers to rapidly pioneer and equitably deploy
innovative solutions that can prevent and cure cancer.
"Beating cancer demands bold innovation and deliberate
collaboration. CancerX is creating a dynamic ecosystem where ideas
can flourish, expertise and resources can be shared, and innovative
solutions can be rapidly developed and equitably deployed in the
fight against cancer. As a co-host, we take immense pride in the
diverse and inclusive community of pioneers coming together as
members, all driven by a shared commitment to advancing the goals
of the Cancer Moonshot. Together, we will advance the frontiers of
cancer research and treatment through digital innovation, while
striving to reduce the incidence and burden of cancer for all
people." said Santosh Mohan, Vice
President, Digital, Moffitt Cancer Center.
While data analysis in the lab can be costly, siloed and time
intensive, SOPHiA GENETICS' technology breaks down these barriers,
facilitating information-sharing and streamlined data analysis. The
SOPHiA DDM™ Platform will not only help bring CancerX partner data
together but will accelerate research work to help facilitate
breakthroughs.
"Multi-stakeholder collaboration is critical to harness the
potential of digital innovation in the fight against cancer, and
we're honored to partner with SOPHiA GENETICS to achieve the
ambitious goals of CancerX," said Smit
Patel, Associate Program Director at DiMe. "Through this
impressive collaboration, we will establish best practices, build
capacity, and demonstrate the impact of innovation on the life of
every person on a cancer journey."
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook,
and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-joins-cancerx-to-help-accelerate-cancer-research-301840823.html
SOURCE SOPHiA GENETICS